Alto Neuroscience (ANRO) Equity Average (2023 - 2026)

Alto Neuroscience has disclosed Equity Average across 4 years of filings, most recently posting $197.3 million for Q1 2026.

• Equity Average for Q1 2026 came in at $197.3 million, up 35.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $197.3 million (up 35.78% YoY), and the FY2025 annual result was $151.3 million, up 279.26% from the prior year.
• Equity Average came in at $197.3 million for Q1 2026 at Alto Neuroscience, up from $131.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $197.3 million in Q1 2026 to a low of -$66.4 million in Q4 2023.
• The 4-year median for Equity Average is $131.3 million (2025), against an average of $94.0 million.
• Across the five-year window, Equity Average surged 481.19% in 2024 and sank 31.86% in 2025, its largest moves.
• Alto Neuroscience's Equity Average stood at -$66.4 million in 2023, then jumped by 338.39% to $158.3 million in 2024, then fell by 17.0% to $131.3 million in 2025, then surged by 50.18% to $197.3 million in 2026.
• The last three Equity Average figures came in at $197.3 million (Q1 2026), $131.3 million (Q4 2025), and $117.5 million (Q3 2025), per Business Quant data.